Advertisement
Screener

EVOLUS, INC. (EOLS) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

EVOLUS, INC. Increase Decrease In Operating Lease Liability

EVOLUS, INC. (EOLS) reported Increase Decrease In Operating Lease Liability of -$840.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05

  • EVOLUS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$429.00K.
  • EVOLUS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$411.00K.
  • EVOLUS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$212.00K.
  • EVOLUS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$290.00K.
  • EVOLUS, INC. increase decrease in operating lease liability for fiscal 2025 was -$758.00K.
  • EVOLUS, INC. increase decrease in operating lease liability for fiscal 2024 was -$716.00K.
  • EVOLUS, INC. increase decrease in operating lease liability for fiscal 2023 was -$907.00K.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$429.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$840.00K
10-Q · filed 2026-08-05
-$1.05M
derived: sum of 3 quarters · filed 2026-08-05
-$1.34M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31-$411.00K
10-Q · filed 2026-05-04
-$623.00K
derived: sum of 2 quarters · filed 2026-05-04
-$913.00K
derived: sum of 3 quarters · filed 2026-05-04
-$1.09M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$212.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03
-$502.00K
derived: sum of 2 quarters · filed 2026-03-03
-$679.00K
derived: sum of 3 quarters · filed 2026-08-05
-$758.00K
10-K · filed 2026-03-03
2025-09-30-$290.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$467.00K
derived: sum of 2 quarters · filed 2026-08-05
-$546.00K
10-Q · filed 2025-11-05
-$740.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30-$177.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$256.00K
10-Q · filed 2026-08-05
-$450.00K
derived: sum of 3 quarters · filed 2026-08-05
-$619.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$79.00K
10-Q · filed 2026-05-04
-$273.00K
derived: sum of 2 quarters · filed 2026-05-04
-$442.00K
derived: sum of 3 quarters · filed 2026-05-04
-$624.00K
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31-$194.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03
-$363.00K
derived: sum of 2 quarters · filed 2026-03-03
-$545.00K
derived: sum of 3 quarters · filed 2026-03-03
-$716.00K
10-K · filed 2026-03-03
2024-09-30-$169.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$351.00K
derived: sum of 2 quarters · filed 2025-11-05
-$522.00K
10-Q · filed 2025-11-05
2024-06-30-$182.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$353.00K
10-Q · filed 2025-08-05
2024-03-31-$171.00K
10-Q · filed 2025-05-07
2023-12-31-$907.00K
10-K · filed 2026-03-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ARVINAS, INC. (ARVN)United States$0.510B58.38
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Altimmune, Inc. (ALT)United States$0.593B-6.43